BRAFTOVI® and ERBITUX® - for Colon Cancer
BRAFTOVI® (Encorafenib) and ERBITUX® (Cetuximab) - for adult patients with metastatic Colorectal Cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
BRAFTOVI® may be taken with or without food. Treatment given until disease progression or unacceptable toxicity. MONITOR PATIENT FOR ONE HOUR AFTER LOADING DOSE OF ERBITUX® (Cetuximab). Monitor for skin rash, diarrhea, and infusion-related reactions.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
BRAFTOVI® (Encorafenib) PO 300 mg QD q28 N/A N/A N/A
ERBITUX® (Cetuximab) IV 400 mg/m2 D1 N/A premixed NONE 120 minutes
ERBITUX® (Cetuximab) IV 250 mg/m2 D8, D15, D22 q28 premixed NONE 60 minutes